MiNK Therapeutics Reports $3.1 Million Net Loss in Q2 2026, Decreases from Previous Year

MiNK Therapeutics, Inc. reported a net loss of $3.1 million for the second quarter of 2026, a decrease from a net loss of $4.2 million in the same period of the previous year. For the first half of 2026, the company recorded a net loss of $5.9 million, down from $7.0 million in the first half of 2025. The reduction in losses is attributed to a decrease in general and administrative expenses, which fell by 28% to $1.3 million in Q2 2026, primarily due to lower share-based compensation and professional fees. Research and development expenses remained relatively stable, totaling $1.9 million for the second quarter, reflecting ongoing clinical trial activities.

As of June 30, 2026, MiNK's total assets were reported at $9.6 million, a significant decrease from $14.2 million at the end of 2025. The decline in assets was primarily driven by a reduction in cash and cash equivalents, which decreased to $8.8 million from $13.4 million at the end of the previous fiscal year. The company's total liabilities also decreased to $23.6 million from $27.5 million, largely due to the repayment of a related party note of $5 million in January 2026. Despite these changes, MiNK continues to face a substantial accumulated deficit of $162.5 million.

In terms of operational developments, MiNK is advancing its lead product candidate, agenT-797, which is currently in clinical trials for various indications, including solid tumors and critical pulmonary immune failure. The company has treated nearly 100 patients with agenT-797, generating insights that support its continued development. MiNK is also exploring collaborations and partnerships to enhance its product pipeline and secure additional funding, as it anticipates ongoing operating losses until it can generate sales.

The company has been proactive in its financing efforts, having entered into a Sales Agreement with B. Riley Securities to sell shares of its common stock, with net proceeds of approximately $4.4 million generated in the first half of 2026. MiNK's management has indicated that while they believe their current cash position and anticipated funding will meet liquidity requirements for over a year, there remains substantial doubt about the company's ability to continue as a going concern without additional funding. The company is actively seeking strategic partnerships and exploring non-dilutive financing options to bolster its financial position.

Looking ahead, MiNK Therapeutics is focused on advancing its clinical programs and expanding its pipeline of engineered iNKT cell therapies. The company is optimistic about the potential of its product candidates, particularly in addressing unmet medical needs in oncology and immune-mediated diseases. However, the path to commercialization remains uncertain, with significant expenditures anticipated for clinical trials and regulatory approvals. MiNK's future performance will depend on its ability to navigate these challenges and secure the necessary funding to support its operations and growth initiatives.